Skip to main content

News

Shingles Risk with JAK Inhibitors and Other Biologics

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Combo Methotrexate and Leflunomide Safety in RA

Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.

Cardiovascular Prevention Lacking in Rheumatoid Arthritis

An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).

CDC Reverses Stance on Masks

Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.

US News & World Report Ranks Best Rheumatology Hospitals

Medscape has published the annual U.S. News and World Reports ranking of Rheumatology Hospitals, again honoring Johns Hopkins Hospital with the top spot, with runner up status going to the Cleveland Clinic, Hospital for Special Surgery, Mayo Clinic and Brigham and Women's Hospital.

Rheumatoid Poor Outcomes Not Linked to Comorbidity

Disease activity leads to poor outcomes; but does comorbidity add to this?  A recent analysis suggests that while comorbidities do not affect long-term, functional outcomes, sociodemographic factors do affect outcomes in rheumatoid Arthritis (RA).

DMARD Effects on COVID-19 Outcomes

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs)

RheumNow Podcast – World Going to Pot (7.23.2021)

Bicycles, Tramadol, biologics - these are but a few of my favorites things in today's broadcast. Join me as I review the news and journal articles from this past week on RheumNow.com.

Fracture Risk with Low Dose Steroid

A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. 

Tofacitinib Efficacy in Ankylosing Spondylitis

Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and is safe. 

Growing Cannabis Use in Arthritis Patients

The National Databank for Rheumatic Diseases reports a significant increased in cannabis use amongst arthritis patients between 2014-2019, suggesting patients are more frequently engaged in self-management of pain and the unmet need for a pain relieving, opioid-sparing alternative.

×